As of 2025-10-29, the EV/EBITDA ratio of Foghorn Therapeutics Inc. (FHTX) is -2.14. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FHTX's latest enterprise value is 178.99 mil USD. FHTX's TTM EBITDA according to its financial statements is -83.81 mil USD. Dividing these 2 quantities gives us the above FHTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.6x - 15.6x | 15.2x |
| Forward P/E multiples | 17.5x - 35.2x | 20.1x |
| Fair Price | (24.72) - (21.91) | (24.89) |
| Upside | -655.6% - -592.2% | -659.2% |
| Date | EV/EBITDA |
| 2025-10-27 | -1.91 |
| 2025-10-24 | -1.88 |
| 2025-10-23 | -1.76 |
| 2025-10-22 | -1.84 |
| 2025-10-21 | -1.88 |
| 2025-10-20 | -1.86 |
| 2025-10-17 | -1.83 |
| 2025-10-16 | -2.04 |
| 2025-10-15 | -2.12 |
| 2025-10-14 | -2.07 |
| 2025-10-13 | -2.03 |
| 2025-10-10 | -1.87 |
| 2025-10-09 | -2.12 |
| 2025-10-08 | -2.17 |
| 2025-10-07 | -2.12 |
| 2025-10-06 | -2.19 |
| 2025-10-03 | -2.26 |
| 2025-10-02 | -2.20 |
| 2025-10-01 | -2.46 |
| 2025-09-30 | -2.43 |
| 2025-09-29 | -2.51 |
| 2025-09-26 | -2.41 |
| 2025-09-25 | -2.30 |
| 2025-09-24 | -2.45 |
| 2025-09-23 | -2.51 |
| 2025-09-22 | -2.49 |
| 2025-09-19 | -2.52 |
| 2025-09-18 | -2.60 |
| 2025-09-17 | -2.37 |
| 2025-09-16 | -2.44 |
| 2025-09-15 | -2.50 |
| 2025-09-12 | -2.63 |
| 2025-09-11 | -2.70 |
| 2025-09-10 | -2.61 |
| 2025-09-09 | -2.80 |
| 2025-09-08 | -3.01 |
| 2025-09-05 | -3.03 |
| 2025-09-04 | -2.77 |
| 2025-09-03 | -2.69 |
| 2025-09-02 | -2.70 |
| 2025-08-29 | -2.55 |
| 2025-08-28 | -2.51 |
| 2025-08-27 | -2.78 |
| 2025-08-26 | -2.86 |
| 2025-08-25 | -2.68 |
| 2025-08-22 | -2.88 |
| 2025-08-21 | -2.53 |
| 2025-08-20 | -2.68 |
| 2025-08-19 | -2.39 |
| 2025-08-18 | -2.57 |